In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...

Thousands of pediatric cancer patients have benefited from cutting-edge advances in treatment, the American Association for ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...

First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability ...

Graft-versus-host disease (GVHD) is a potential post-transplant complication. Here’s how one patient and his wife are ...

The Mikaela Naylon Give Kids a Chance Act now heads to the Senate, aiming to fast-track treatments and give children with ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

TIBSOVO is a targeted therapy that works against an abnormal protein created by a mutation in the IDH1 gene. This abnormal ...

A new report highlights the stories of kids who have survived cancer and the importance of research funding.

Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical ...

A combination of two therapies, azacitidine and venetoclax, or aza-ven, outperformed intensive chemotherapy for acute myeloid leukemia in patients healthy enough to receive aggressive treatment, ...